<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T1" position="float">
 <label>Table 1</label>
 <caption>
  <p>Main treatments, currently in use, and under investigation, in COVID-19 patients.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>Main drugs in use</bold>
    </th>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>Mechanism of action</bold>
    </th>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>Comment</bold>
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Antivirals</bold>
    </td>
    <td rowspan="1" colspan="1"/>
    <td rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Lopinavir/Ritonavir</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Protease inhibitor</td>
    <td valign="top" align="left" rowspan="1" colspan="1">A RCT showed no benefit compared to control group (
     <xref rid="B87" ref-type="bibr">87</xref>)
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Chloroquine/Hydroxychloroquine ± azithromycin</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Increases endosomal pH</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Not reduced risk of death in a study of 1,376 patients (
     <xref rid="B88" ref-type="bibr">88</xref>)
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Favipiravir</td>
    <td valign="top" align="left" rowspan="1" colspan="1">RNA-dependent RNA polymerase inhibitor</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Improved symptoms but not higher recovery rate in a RCT (
     <xref rid="B89" ref-type="bibr">89</xref>)
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Remdesivir</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Nucleoside analog inhibitors</td>
    <td valign="top" align="left" rowspan="1" colspan="1">One RCT showed faster recovery, another did not evidence clinical improvement (
     <xref rid="B90" ref-type="bibr">90</xref>, 
     <xref rid="B91" ref-type="bibr">91</xref>)
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Convalescent plasma</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Plasma with anti-SARS-CoV2 Ab</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Effective and safe in some case reports (
     <xref rid="B92" ref-type="bibr">92</xref>)
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" colspan="3" rowspan="1">
     <bold>Anti-inflammatories</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Steroids</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Broad anti-inflammatory effects, including inhibition of multiple cytokine expression</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Increased death in a retrospective study on 548 patients (
     <xref rid="B93" ref-type="bibr">93</xref>). In a retrospective study on 201 patients methylprednisolone was beneficial in those with severe disease (
     <xref rid="B94" ref-type="bibr">94</xref>)
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">IVIg</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Block FcR activation</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Only retrospective studies or case reports (
     <xref rid="B95" ref-type="bibr">95</xref>)
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Tocilizumab</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Recombinant humanized anti-IL-6R monoclonal Ab</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Improved symptoms in retrospective studies (
     <xref rid="B96" ref-type="bibr">96</xref>)
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Anakinra</td>
    <td valign="top" align="left" rowspan="1" colspan="1">IL-1 receptor antagonist</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Clinical improvement in a retrospective study (
     <xref rid="B97" ref-type="bibr">97</xref>)
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Eculizumab</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Humanized anti-C5 monoclonal Ab</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Ongoing trials</td>
   </tr>
   <tr>
    <td valign="top" align="left" colspan="3" rowspan="1">
     <bold>Others</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Stem Cells Therapy</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Anti-inflammatory and immune regulatory effects</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Only case reports. Numerous ongoing trials</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Heparin</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Anticoagulant</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Improved hypoxia in a case series (not peer-reviewed) (
     <xref rid="B98" ref-type="bibr">98</xref>)
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" colspan="3" rowspan="1">
     <bold>Drugs under investigation</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" colspan="3" rowspan="1">
     <bold>Antivirals</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Camostat mesilate</td>
    <td valign="top" align="left" rowspan="1" colspan="1">TMPRSS2 inhibitor</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Ongoing trials</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Arbidol (Umifenovir)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Inhibitor of virus-mediated fusion with target membrane</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Not improvement in a retrospective study (
     <xref rid="B99" ref-type="bibr">99</xref>)
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Bromhexine hydrochloride</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Transmembrane protease serine inhibitor</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Ongoing trials</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Danoprevir</td>
    <td valign="top" align="left" rowspan="1" colspan="1">HCV NS3 protease inhibitor</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Efficacy proved in a small open clinical trial (not peer-reviewed) (
     <xref rid="B100" ref-type="bibr">100</xref>)
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Interferons</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Broad spectrum antivirals</td>
    <td valign="top" align="left" rowspan="1" colspan="1">RCT proved benefit in triple therapy (
     <xref rid="B101" ref-type="bibr">101</xref>)
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Nitric Oxide Gas</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Inhibits viral protein and RNA synthesis</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Ongoing trials</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Oseltamivir</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Viral neuraminidase inhibitor</td>
    <td valign="top" align="left" rowspan="1" colspan="1">No effective outcomes in a retrospective study on 138 patients (
     <xref rid="B102" ref-type="bibr">102</xref>)
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" colspan="3" rowspan="1">
     <bold>Anti-inflammatories</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Baricitinib</td>
    <td valign="top" align="left" rowspan="1" colspan="1">JAK/STAT inhibitor</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Clinical improvement in a case series (
     <xref rid="B103" ref-type="bibr">103</xref>)
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Bevacizumab</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Monoclonal anti-VEGF Ab</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Ongoing trials</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Clazakizumab</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Humanized monoclonal anti-IL-6 Ab</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Ongoing trials</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Colchicine</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Inhibition of the assembly of the NLRP3 inflammasome</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Ongoing trials</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Fingolimod</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Sphingosine-1-phosphate receptor regulator</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Ongoing trials</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Naproxen</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Inhibitor of both COX-2 of Influenza A virus NP</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Ongoing trials</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Pirfenidone</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Inhibits IL-1β and IL-4</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Ongoing trials</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Ruxolitinib</td>
    <td valign="top" align="left" rowspan="1" colspan="1">JAK 1 and JAK 2 inhibitor</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Ongoing trials</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Sarilumab</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Recombinant human anti-IL6R monoclonal Ab</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Preliminary data from an ongoing RCT showed decreased inflammatory markers in treatment group</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Siltuximab</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Anti-IL-6 chimeric monoclonal Ab</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Decrease inflammatory markers in a retrospective study (
     <xref rid="B104" ref-type="bibr">104</xref>)
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Thalidomide</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Reduces TNFα</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Ongoing trials</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Ulinastatin</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Reduces TNFα, IL-6, and IFN-γ and increases IL-10</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Ongoing trials</td>
   </tr>
   <tr>
    <td valign="top" align="left" colspan="3" rowspan="1">
     <bold>Others</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Losartan</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Angiotensin II receptor blocker</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Safe according to large retrospective studies (
     <xref rid="B105" ref-type="bibr">105</xref>, 
     <xref rid="B106" ref-type="bibr">106</xref>)
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Carrimycin</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Macrolide antibiotic</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Ongoing trials</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Vitamin C</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Antioxidant properties</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Ongoing trials</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>Ab: antibody; COX-2: cyclooxygenase-2; HCV: hepatitis C virus; IL-6R: interleukin-6 (IL-6) receptor; NLRP3: NLR Family Pyrin Domain Containing 3; RCT: randomized controlled trial; TMPRSS2: transmembrane serine protease 2; TNFα: tumor necrosis factor α; VEGF: vascular endothelial growth factor</italic>.
  </p>
 </table-wrap-foot>
</table-wrap>
